Biomarker Screening and Identification Service
InquiryIdentifying the right biological markers is not just a technical step; it's the compass that guides the entire drug discovery journey. At Protheragen, we specialize in pinpointing these critical indicators during the preclinical phase to help you understand exactly how your candidate molecule interacts with complex biological systems.
Advanced Preclinical Biomarker Screening: Accelerating Target Identification and Drug Development
By focusing strictly on preclinical research, we provide a deep dive into pharmacodynamics, target engagement, and safety signals before you ever move toward human studies. We basically help you find the "smoking gun" in the data that proves your drug is doing exactly what it's supposed to do.
Core Technologies
To get high-quality data, you need the right tools, and we have assembled a pretty formidable toolkit here. We don't just stick to one method because biology is never that simple. Instead, we use a mix of high-sensitivity platforms to catch even the faintest signals.
We use this for deep genomic and transcriptomic profiling to see how gene expression shifts in response to treatment.
Platforms like MSD allow us to track dozens of proteins or cytokines simultaneously from a tiny sample volume.
Essential for proteomics and metabolomics when you need to identify unknown molecules or metabolic shifts.
This gives us a granular look at immune cell subsets and their functional states with incredible precision.
We do not just measure "how much" of a marker is there, but exactly where it is located within the tissue architecture.
Solution Scope
Our expertise spans the entire breadth of preclinical biomarker discovery, ensuring no stone is left unturned in your research.
Measuring the biological effect of the drug on the intended target or pathway.
Proving that the drug actually binds to its target in a living system.
Early identification of molecular signatures associated with liver, kidney, or cardiac stress.
- Patient Stratification Markers
Identifying genetic or proteomic signatures in Preclinical Models that can later help define inclusion criteria for trials.
- Mechanism of Action (MoA) Discovery
Uncovering the secondary pathways influenced by your compound to provide a holistic view of its biological impact.
- In Vivo Imaging Biomarkers
Utilizing bioluminescence or fluorescent probes to track disease progression and drug response in real-time.
Contact our experts to build a precision biomarker strategy.
Workflow
Our process is designed to be thorough but flexible, ensuring that every project gets the specific attention it needs to succeed.
Fields of Application
Our biomarker screening services are designed to be highly versatile, providing critical data across a wide range of therapeutic research areas. We help you move beyond basic observation to gain a deep, molecular understanding of your drug's performance.
- Oncology & Immuno-Oncology
We focus heavily on identifying tumor-specific antigens and tracking the modulation of oncogenic signaling pathways. Our screens also help monitor the activation of the immune system, such as T-cell infiltration and cytokine release profiles, to evaluate the efficacy of checkpoint inhibitors and CAR-T therapies.
- Neurology & CNS Disorders
In the challenging field of neuroscience, we look for fluid-based markers (like those in CSF or plasma) that indicate neurodegeneration, neuroinflammation, or neuroprotection. This provides a window into the brain's response to treatment in models for Alzheimer's, Parkinson's, and multiple sclerosis.
- Immunology & Inflammation
We track complex inflammatory cascades and cytokine storms to ensure that anti-inflammatory drugs are hitting their targets without causing systemic safety issues. This is vital for developing treatments for autoimmune diseases like rheumatoid arthritis and Crohn's disease.
- Metabolic & Cardiovascular Diseases
Our platforms allow for the precise tracking of insulin sensitivity markers, lipid profiles, and cardiac stress signals. We help researchers understand how new compounds affect metabolic homeostasis and identify early signs of potential cardiotoxicity.
Advantages
Choosing Protheragen means you're getting more than just a service provider; you're getting a partner who understands the high stakes of drug development.
Precision-Driven Methodology
We do not believe in "one-size-fits-all" panels. Every project is customized to your specific molecule and therapeutic area. This tailored approach ensures that the biomarkers we identify are actually relevant to your drug's specific mechanism, reducing the risk of chasing "false positives" that don't hold up in later stages. It has been shown that this custom-centric approach significantly increases the success rate of translational research programs.
Preclinical Specialization
Because we focus exclusively on the preclinical space, we are experts at handling animal-derived samples and complex in vitro models like organoids. We understand the nuances of cross-species translation and help you select markers that have the highest likelihood of remaining relevant when you eventually move to human trials. Our deep focus ensures that your early-stage data is robust, reproducible, and ready for the scrutiny of regulatory reviewers.
Integrated Multi-Omics Approach
We do not just look at one layer of biology. By integrating genomics, proteomics, and metabolomics into a single workflow, we provide a 360-degree view of your drug's impact. This holistic perspective often uncovers unexpected synergy or hidden toxicities that single-platform services frequently miss, saving you months of potential rework down the line. Our internal benchmarks show that this integrated method identifies 30% more viable biomarker candidates than traditional single-assay approaches.
Advanced Data Interpretation
Our bioinformatics team does more than just hand over a spreadsheet. We provide meaningful biological context, explaining the "why" behind the numbers. We help you interpret how these markers relate to disease pathology and drug efficacy, making the data truly actionable for your development team.
Contact us today to gain a decisive edge in your preclinical research.
Customer Review
Identifying Novel Targets Through Precision Biophysical Screening
"We were struggling to prove that our lead compound was actually hitting its target in our mouse models. Protheragen didn't just run a standard panel; they took the time to understand our drug's unique chemistry. Their team identified a specific phosphorylation event that we had completely overlooked. It was the 'aha!' moment we needed. We're currently planning our next three validation studies with them."
Dr. D. J., Biochemist
Accelerating Discovery with Integrated and Data-Driven Validation
"Working with the scientists at Protheragen felt like having an extension of our own internal team. They were incredibly transparent about the data, even when the results weren't what we expected. That honesty saved us from pursuing a dead-end pathway and helped us pivot our strategy early. Their expertise in preclinical proteomics is probably some of the best I've encountered in my career. We'll definitely be back for our next program."
Dr. S. T., Pharmacologist
Frequently Asked Questions
-
Why should I invest in biomarker screening so early in the preclinical stage?
Finding markers early allows you to define your PK/PD relationship much more clearly. It helps you pick the right dose for your first-in-human trials and acts as an early warning system for toxicity.
-
Can Protheragen help if I don't know what markers to look for?
Absolutely. That's actually where we do our best work. We can run "untargeted" discovery screens using NGS or mass spec to see what changes naturally in your models when the drug is introduced.
-
What kinds of samples do you accept?
We handle everything from standard blood and urine to more difficult samples like fresh-frozen tissue, FFPE slides, and even cerebrospinal fluid or bone marrow aspirates from animal models.
-
How long does a typical discovery project take?
It varies depending on the complexity, but most screening projects—from sample receipt to final report—take between 6 and 10 weeks. We can speed things up if you have a tight regulatory deadline.
-
Do you provide clinical diagnostic services?
No, Protheragen is strictly a preclinical research organization. We specialize in discovery and validation for R&D purposes only, which allows us to be highly agile and focused on the early development pipeline.
-
Can you validate a biomarker I've already found?
Yes, we offer targeted validation services. If you have a specific protein or gene in mind, we can develop and qualify a custom assay to measure it across your various study groups.
-
What makes Protheragen different from a standard CRO?
We are not a "sample factory." We provide high-level scientific consultation. You aren't just buying an assay; you're buying 20 years of expertise in how to interpret complex biological data.
-
How do you handle data security and intellectual property?
Your samples and your data are 100% your property. We have strict firewalls and secure data handling protocols to ensure your confidential project information never leaves our facility.
Contact Us
Protheragen provides a high-end, specialized biomarker screening and identification service tailored specifically for the preclinical research phase. By combining cutting-edge multi-omics platforms with deep biological expertise, we help drug developers identify, validate, and prioritize the biomarkers that matter most for their program's success. Welcome to Contact Protheragen to discuss your project requirements.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.